Cyramza (ramucirumab)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved April 2014

Specific Treatments:

gastric cancer

Therapeutic Areas

General Information

Cyramza (ramucirumab) is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2. As such, it is an angiogenesis inhibitor that blocks the blood supply to tumors.

Cyramza is specifically indicated for advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine- or platinum-containing chemotherapy.

Cyramza is supplied as a solution for intravenous infusion. The recommended dose is 8 mg/kg every two weeks administered as an intravenous infusion over 60 minutes. Continue Cyramza until disease progression or unacceptable toxicity.

Clinical Results

FDA Approval
The FDA approval of Cyramza was based on a multinational, randomized, double-blind study evaluating Cyramza plus best supportive care (BSC) versus placebo plus BSC in 355 subjects with locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction) who previously received platinum- or fluoropyrimidine-containing chemotherapy. The major efficacy outcome measure was overall survival and the supportive efficacy outcome measure was progression-free survival. The subjects treated with Cyramza experienced a median overall survival of 5.2 months compared to 3.8 months in psubjects receiving placebo. Additionally, subjects who took Cyramza experienced a delay in tumor growth (progression-free survival) compared to subjects who were given placebo.

Side Effects

Adverse effects associated with the use of Cyramza may include, but are not limited to, the following:

  • hypertension
  • diarrhea

Mechanism of Action

Cyramza (ramucirumab) b is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF Receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.

Additional Information

For additional information regarding Cyramza or gastric cancer, please visit the Cyramza web page.


[ Home | Discussions | Article Archives | Help | Submit your Site]

Copyright 1996 - 2014 by Gelber Associates All Rights Reserved.